Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
6
Bullish
5
Bearish
18
Neutral
6
Bullish
22
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Bearish
15
Neutral
0
Bullish
17
Discovery themes featuring this stock
Marksans Pharma is a vertically integrated pharmaceutical company engaged in research, manufacturing, marketing and sale of generic formulations across regulated markets, operating R&D centres in Verna, Goa and Navi Mumbai and multiple overseas subsidiaries including Nova Pharmaceuticals and newly formed Marksans Pharma Europe and Marksans (Canada) Inc.
Q1 FY27 was a milestone quarter: consolidated revenue of INR840.8 crores, up 35.6% year‑on‑year, highest ever quarterly EBITDA at INR213 crores and PAT of INR159.4 crores, while net cash crossed INR1,031 crores and cash balance exceeded INR1,058 crores, driven by strong Europe and North America performance plus inventory and FX tailwinds.
Europe accelerated rapidly as a strategic focus: UK and Europe delivered INR356 crores in Q1 (42% of revenue), up 74.7% year‑on‑year, supported by the QliniQ acquisition (INR44 crores contribution) and the establishment of front‑end entities in Ireland and Germany to scale regulated prescriptions markets.
The company emphasises disciplined capital allocation and inorganic growth: management intends to selectively deploy the large cash balance for acquisitions that expand front‑end access in Europe and other geographies, while continuing organic new product launches and R&D investments to build differentiated Rx and OTC portfolios.
Pharmaceuticals & Biotechnology
Pharmaceuticals
14,279 Cr
Moderate Risk
27.4
37.0
1.5
4.7
350.75
156.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6298.05 | 15,745 Cr | 92.83 | 18.04 | 0.57 | 21.49 | 25.53 | 8.53 | ||
795.15 | 15,630 Cr | 22.67 | 2.75 | 1.51 | 11.89 | 10.81 | 7.87 | ||
787.75 | 15,453 Cr | 15.24 | 1.47 | 0.58 | 15.38 | 15.37 | 9.16 | ||
942.40 | 15,012 Cr | 42.72 | 2.12 | 0.53 | 5.62 | 6.41 | 2.26 | ||
315.10 | 14,279 Cr | 27.39 | 4.72 | 0.29 | 13.82 | 17.37 | 13.50 | ||
2215.05 | 13,547 Cr | 68.07 | 18.14 | 0.45 | 24.79 | 27.13 | 16.52 | ||
1229.90 | 12,867 Cr | 46.05 | 6.20 | 0.61 | 13.61 | 18.02 | 12.01 | ||
| Median: 7 Co. | — | 942.40 | 15,012 Cr | 42.72 | 4.72 | 0.57 | 13.82 | 17.37 | 9.16 |
Marksans Pharma Ltd (MARKSANS) is currently trading at 306.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Marksans Pharma is a vertically integrated pharmaceutical company engaged in research, manufacturing, marketing and sale of generic formulations across regulated markets, operating R&D centres in Verna, Goa and Navi Mumbai and multiple overseas subsidiaries including Nova Pharmaceuticals and newly formed Marksans Pharma Europe and Marksans (Canada) Inc. Q1 FY27 was a milestone quarter: consolidated revenue of INR840.8 crores, up 35.6% year‑on‑year, highest ever quarterly EBITDA at INR213 crores and PAT of INR159.4 crores, while net cash crossed INR1,031 crores and cash balance exceeded INR1,058 crores, driven by strong Europe and North America performance plus inventory and FX tailwinds. Europe accelerated rapidly as a strategic focus: UK and Europe delivered INR356 crores in Q1 (42% of revenue), up 74.7% year‑on‑year, supported by the QliniQ acquisition (INR44 crores contribution) and the establishment of front‑end entities in Ireland and Germany to scale regulated prescriptions markets. The company emphasises disciplined capital allocation and inorganic growth: management intends to selectively deploy the large cash balance for acquisitions that expand front‑end access in Europe and other geographies, while continuing organic new product launches and R&D investments to build differentiated Rx and OTC portfolios.
Over the past 52 weeks, Marksans Pharma Ltd has traded between a low of ₹156.00 and a high of ₹350.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Marksans Pharma Ltd has a market capitalization of approximately 14,279.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Marksans Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 27.39 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 14,279.19 Cr, Marksans Pharma Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Marksans Pharma Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Marksans Pharma Ltd is 27.39. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Operating revenue was ₹840.8 crore in Q1 FY27, up 35.6% year-on-year from ₹620.0 crore.
The most significant announcement is the 'Biopharma Shakti' scheme, a ₹10,000 crore initiative aimed at making India a global biopharmaceutical manufacturing hub, which will strengthen the entire industry ecosystem.
Upcoming Result Date: Nov 03, 2026
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
